Quarterly ResultApr 28, 2026, 04:01 PM
DSGN Q1 Net Loss $(17.6)M; $222.8M Cash; Clinical Progress
AI Summary
Design Therapeutics, Inc. reported a net loss of $(17.6) million for the first quarter of 2026. The company ended the quarter with $222.8 million in cash, cash equivalents, and investment securities, providing a runway into 2029. DSGN highlighted continued progress in its clinical programs, including ongoing dosing in the RESTORE-FA trial for Friedreich ataxia and a Phase 2 trial for Fuchs Endothelial Corneal Dystrophy, with data expected in the second half of 2026. Additionally, the company appointed David Shapiro, M.D., to its Board of Directors.
Key Highlights
- DSGN Q1 2026 net loss was $(17.6) million.
- Cash, cash equivalents, and investment securities totaled $222.8 million as of March 31, 2026.
- R&D expenses were $14.4 million for Q1 2026.
- G&A expenses were $5.3 million for Q1 2026.
- RESTORE-FA trial (DT-216P2 for Friedreich ataxia) continues dosing; update expected H2 2026.
- Phase 2 trial of DT-168 for FECD ongoing; data anticipated H2 2026.
- Phase 1 trial of DT-818 for DM1 expected to begin dosing in H1 2026.
- David Shapiro, M.D., appointed to the Board of Directors in March 2026.